GH Research PLC (GHRS)
| Market Cap | 1.23B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.26M |
| Shares Out | 62.03M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,759 |
| Open | 19.47 |
| Previous Close | 19.60 |
| Day's Range | 18.93 - 20.11 |
| 52-Week Range | 8.75 - 24.66 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 41.38 (+108.88%) |
| Earnings Date | May 1, 2026 |
About GHRS
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology tr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price target is $41.38, which is an increase of 108.88% from the latest price.
News
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash...
FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years
The U.S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's (NASDAQ: GHRS) Investigational New Drug Application (IND) for GH001.
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted f...
GH Research to Announce IND Status for GH001
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
Engagement with FDA on GH001 IND complete response ongoing Full dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025 Long-term clinical data on safety and efficacy from Open-...
Depression-Focused GH Research Shares Could See Significant Upside: Analyst
Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company's lead drug candidate, GH-001, which had demonstrated impressive efficacy in Phase 2 versus competition.
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 mont...
GH Research Announces Global Pivotal Program Plans and Further Development Updates
DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing tr...
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing tr...
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate...
GH Research Announces Pricing of $150 Million Public Offering
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research Announces Proposed Public Offering
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
Why Is GH Research Stock Trading Higher On Monday?
On Monday, GH Research PLC GHRS said its Phase 2b trial with GH001, an inhalable bufotenin product candidate for treatment-resistant depression, met its primary endpoint.
GH Research Transcript: Status Update
GH001 showed rapid, robust, and sustained efficacy in TRD, with a high remission rate and favorable safety profile. Long-term data indicate durable remission with infrequent treatments and fewer clinic visits compared to current standards.
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo...